Floatz logo

Recombinant Human Interleukin-2

Lymphoblastic Lymphoma

Masonic Cancer Center, University of MinnesotaN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

54 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
VINDESINE
University Hospital Muenster
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
Cyclophosphamide
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Human Interleukin-2 is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
60 / 100
View asset →
Brain Injury, AcuteDormant
B
Indicative ·
57 / 100
View asset →
LeukemiaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →